## CLX: Clorox Company (The) - XLP: Consumer Defensive

### Executive Summary

No thesis match: MRS_20 -5.4% below STRENGTH zone (4.0-10.0%); PEG 3.35 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge. Caution: momentum weakening (-3.8% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($93.56)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_20 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Neutral (Bullish: 2, Bearish: 0)

**1. How ERP Rollout Disruptions and an Earnings Beat At Clorox (CLX) Has Changed Its Investment Story**
- Source: Simply Wall Street | 20251218T233311 | Somewhat-Bullish | Relevance: 100%
- Clorox recently reported third-quarter revenue that, while down 18.9% year-on-year, exceeded analyst estimates, despite temporary market share losses due to a new ERP system rollout. This system upgrade is central to management's transformation plan, aiming for productivity gains and cost optimization. Investors are now weighing how effectively this ERP implementation translates into sustained benefits against the backdrop of persistent price competition and weak share price performance.

**2. Understanding the Setup: (CLX) and Scalable Risk**
- Source: Stock Traders Daily | 20251217T231400 | Somewhat-Bearish | Relevance: 100%
- This article analyzes Clorox Company (CLX), indicating a near-term neutral sentiment amidst mid and long-term weakness. It highlights an exceptional 22.5:1 risk-reward short setup, signaling potential downside, and outlines three distinct AI-generated trading strategies for different risk profiles.

**3. The Clorox Company (NYSE:CLX) Receives Consensus Rating of "Reduce" from Analysts**
- Source: MarketBeat | 20251218T073958 | Somewhat-Bearish | Relevance: 100%
- The Clorox Company (NYSE:CLX) has received a consensus "Reduce" rating from analysts, with an average 1-year price target of $125.00. Several firms recently lowered their price targets, despite Clorox beating quarterly EPS estimates. The company reported $0.85 EPS against an estimate of $0.78, though revenue declined by 18.9% year-over-year.

**4. Clorox (CLX) Rating: Citigroup Lowers Price Target to $109.00**
- Source: GuruFocus | 20251217T214001 | Somewhat-Bearish | Relevance: 100%
- Citigroup has reaffirmed its Neutral rating on Clorox (CLX) but has reduced its price target from $120.00 to $109.00, indicating a downward revision of 9.17% in the expected valuation. This adjustment by analyst Filippo Falorni follows a series of similar price target reductions by other firms like JP Morgan, Wells Fargo, and Morgan Stanley in recent months. Despite these adjustments, the average target price from 17 analysts suggests a potential upside for Clorox, and GuruFocus estimates a fair value for the stock above its current trading price.

**5. Clorox (NYSE:CLX) Price Target Lowered to $109.00 at Citigroup**
- Source: MarketBeat | 20251217T144308 | Somewhat-Bearish | Relevance: 100%
- Citigroup has lowered its price target for Clorox (NYSE:CLX) to $109 from $120, maintaining a "neutral" rating. This implies an 8.1% upside, despite the company recently beating EPS estimates but experiencing an 18.9% year-over-year revenue decline and setting FY2026 EPS guidance. Several other brokerages have also adjusted their price targets and ratings on Clorox.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 0, Lowers: 1)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-17 | Citigroup | $109 | $120 | -9% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-17 | Citigroup | main | Neutral |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_BUYING** |
| Buys | 12 ($10.20M) |
| Sells | 11 ($0.63M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 44.7% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 8 / 2 |

**Top Holders:**
- Vanguard Group Inc: 12.9% (-0.7%)
- Blackrock Inc.: 8.5% (-1.2%)
- State Street Corpora: 6.9% (+3.5%)
- Invesco Ltd.: 3.3% (+23.1%)
- Morgan Stanley: 2.6% (+18.3%)

### Key Risks

1. Momentum deterioration: MRS_20 falling (-3.8% 5d) with bearish MACD, trend may be turning.
2. Valuation stretched: PEG 3.3x requires aggressive growth execution.
3. Long-term trend broken: trading 21.2% below SMA200.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 3.35 signals overvaluation risk, limited margin of safety. Quality metrics strong (ROE 44%, ROA 12%). Analyst sentiment negative (1 target cuts vs 0 raises). Insider buying signal ($10.2M), management confidence. Institutional flow bullish (8 buying vs 2 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $12.0B |
| Beta | 0.57 |
| 52W Range | $98.20 - $165.00 |
| Short Interest | 6.5% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 3.35 |
| Forward P/E | 14.5 |
| Current P/E | 16.4 |
| YoY Growth | 12.9% |
| EPS Direction | STABLE |

### Technicals

MRS_20 deteriorating from -1.6% to -5.4% (-3.8% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 9.4pp (needs >4.0% for momentum thesis). AM_20 at -5.1% indicates price below own 20MA trend. Underperforming sector by 5.2pp, stock-specific weakness. Below SMA200 (0.79x), long-term trend not supportive. Elevated volume (1.8x 20MA), institutional activity likely. OFD pattern: -MTH (Decline).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -5.43% (CS: 9) | Weak |
| RSI_14 | 34.1 | Neutral |
| MACD Histogram | -0.17 | Bearish |
| vs SMA20 | 0.949x | Below |
| vs SMA50 | 0.909x | Below |
| vs SMA200 | 0.788x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $98.30
- **Stop Loss:** $93.56 (4.8% risk)
- **Target:** $103.04 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 253
- **Position Value:** $24,869.90
- **Portfolio %:** 24.87%
- **Risk Dollars:** $1,200.00
- **Risk Per Trade:** 1.20%
- **Modifiers:** L1 120% | L2 100% | Combined 1.20x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.20x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with improving risk appetite as VIX falls to 6th percentile and tech rally resumes on AI infrastructure demand. Fed pause expectations from cooling CPI data support equities, though elevated put/call ratio suggests cautious positioning. Focus on quality names in AI-exposed sectors.*

### Earnings

**Next:** 2026-02-03 (Est: $1.45)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $0.78 | $0.85 | +9.2% |
| 2025Q2 | $2.21 | $2.87 | +29.8% |
| 2025Q1 | $1.56 | $1.45 | -6.9% |
| 2024Q4 | $1.40 | $1.55 | +10.7% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*